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RESEARCH ARTICLE
A journey from the endothelium to the tumor tissue: distinct behavior between
PEO-PCL micelles and polymersomes nanocarriers
Agathe Figarola,b, Laure Gibota, Muriel Golzioa, Barbara Lonettib, Anne-Françoise Mingotaudb and Marie-
Pierre Rolsa
aInstitut de Pharmacologie et Biologie Structurale, IPBS, Universite de Toulouse, CNRS, UPS, Toulouse, France; bLaboratoire des IMRCP,
Universite de Toulouse CNRS UMR, Toulouse, France
ABSTRACT
Polymeric nanocarriers must overcome several biological barriers to reach the vicinity of solid tumors
and deliver their encapsulated drug. This study assessed the in vitro and in vivo passage through the
blood vessel wall to tumors of two well-characterized polymeric nanocarriers: poly(ethyleneglycol-b-
e-caprolactone) micelles and polymersomes charged with a fluorescent membrane dye (DiO: 3,3’-dio-
ctadecyloxacarbo-cyanine perchlorate). The internalization and translocation from endothelial (human
primary endothelial cells HUVEC) to cancer cells (human tumor cell line HCT-116) was studied in con-
ventional 2D monolayers, 3D tumor spheroids, or in an endothelium model based on transwell assay.
Micelles induced a faster DiO internalization compared to polymersomes but the latter crossed the
endothelial monolayer more easily. Both translocation rates were enhanced by the addition of a pro-
inflammatory factor or in the presence of tumor cells. These results were confirmed by early in vivo
experiments. Overall, this study pointed out the room for the improvement of polymeric nanocarriers
design to avoid drug losses when crossing the blood vessel walls.
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Introduction
Conventional anti-cancer treatments can lead to heavy side-
effects. The use of nanocarriers aims at overriding nonspe-
cific toxicity by optimizing the delivery of therapeutic agents
while increasing their efficiency. The on-site delivery of the
encapsulated compounds must overcome numerous
defenses from the human body: biodegradation, opsoniza-
tion and excretion, physiological barriers, and cellular-based
mechanisms of drug resistance. This is a partial explanation
for the nanocarrier’s long and complex development and
their low clinical translation ‘from bench to bed.’ Recently,
Wilhelm et al. (2016) reviewed 10 years of research on nano-
medicine and concluded that the essential nanocarriers’
weakness was a too low ratio of administered versus deliv-
ered dose. According to his systematic literature review, this
ratio reaches only a median of 0.7% in solid tumors. This art-
icle has been moderated, notably, because the specific con-
text of nanomedicine can hardly be compared to the small
molecules drugs’ one (Torrice, 2016). However, its perspec-
tive on the field remains interesting. To reach the targeted
tumor after intravenous injection, nanocarriers must cross
the endothelium formed by endothelial cells. This semi-per-
meable and size-selective barrier, lining the interior surface
of blood vessels, controls the transport of gases, nutrients, or
other materials through para- or transcellular ways. Tight
intercellular junctions limit the paracellular passage to par-
ticles smaller than 6 nm in the general health conditions
(Komarova & Malik, 2010). Transcellular passage is restricted
by endosome vesicular transport. Accordingly, nanocarriers
from 10 to 100 nm should only cross the healthy endothe-
lium in minimal quantity. However, the path to tumor cells
might be facilitated thanks to the enhanced permeability
and retention phenomenon (EPR). The EPR theory, first
described by Matsumura & Maeda (1986), stated that tumor
environment triggers an increase in the endothelium perme-
ability. The EPR effect is a complex phenomenon linked to
(1) the angiogenesis leading to hypervascularity and facilitat-
ing access to the tumor environment for nanocarriers, (2) a
change in the endothelium architecture leading to a higher
permeability of the blood vessels, and (3) an alteration of the
lymphatic system limiting the clearance of the nanocarriers
once they have reached the tumor (Dvorak et al., 1988;
Baban & Seymour, 1998; Maeda, 2001).
The choice of the nanocarrier and its physicochemical
properties has an utterly important impact on tumor target-
ing efficiency. Amphiphilic block copolymers consist in the
covalent association of a hydrophilic and a hydrophobic
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polymer. In appropriate solvents, and under appropriate tem-
perature and shear stress, they can self-assemble to form
polymeric self-assemblies with hydrophobic and hydrophilic
compartments. The hydrophilic and hydrophobic weight frac-
tions of the chosen block co-polymer dictate different self-
assemblies geometries. Although far from universal, a hydro-
philic weight fraction over 50% tends to result in micelles,
whereas a hydrophilic fraction from 25% to 45% favors poly-
mersomes (Discher & Eisenberg, 2002; Liu et al., 2012;
Grossen et al., 2017). With larger diameters, polymersomes, a
polymeric analog of liposomes, have the perk of being able
to encapsulate both hydrophilic and hydrophobic com-
pounds. Simpler to apprehend, micelles have been widely
studied, but polymersomes are considered as particularly
relevant for nanomedicine due to their tunable and higher
encapsulation capacity (Balasubramanian et al., 2016). Other
morphologies such as elongated micelles or vesicles are also
possible. All these biodegradable polymeric self-assemblies
were described as offering a balanced relationship among
long blood circulation, robust encapsulation, tunable chemis-
try, and flexible structure (Soppimath et al., 2001; Christian
et al., 2009; Li et al., 2016). Poly(ethyleneoxide-b-e-caprolac-
tone) (PEO-PCL) vesicles are one of the most promising can-
didates (Grossen et al., 2017). Both polyethylene oxide (PEO,
often also called polyethylene glycol (PEG)) and polycaprolac-
tone (PCL) are considered as biocompatible and have been
approved by health-care authorities such as the Food Drug
Administration (FDA) for use in drug delivery (Sui et al.,
2015) and PEO-PCL nanocarriers seem to trigger no cytotox-
icity (Zhang et al., 2013; Gibot et al., 2014; Sui et al., 2015).
There are, moreover, abundant publications on the use of a
PEGylated surface to increase blood circulation time of nano-
carriers by avoiding opsonization (Li et al., 2014; Owens III &
Peppas, 2006). To reach a balance between low excretion
rate and high encapsulation potency, Alexis et al. (2008) sug-
gested an optimal size of PEGylated-nanocarriers between 10
and 100 nm and Grossen et al. (2017) between 6
and 500 nm. In this size range, PEO-PCL micelles (PEO-PCL
5000-4000 g.mol1) and PEO-PCL polymersomes (PEO-PCL
5000-11000 g.mol1) were chosen following previous studies
of our laboratories confirming their efficiency as nanocarriers
of pheophorbide A for photodynamic therapy (Gibot et al.,
2014; Till et al., 2016a, 2016c).
The goal of this study was to compare the interaction of
two nanocarriers’ (micelles and polymersomes) path from
endothelium lining blood vessels to the tumor cells. In this
study, to avoid cytotoxicity and for biological imaging con-
venience, the encapsulated agent was not a therapeutic one
but the green fluorophore DiO (3,30-dioctadecyloxacarbo-cya-
nine perchlorate). First, we assessed the carrier’s internaliza-
tion by human endothelial cells (HUVEC) and determined if
there is specificity in internalization between those cells and
human colorectal carcinoma cells (HCT-116). We then
assessed the nanocarriers’ ability to cross the endothelium in
healthy conditions and in the vicinity of cancer cells to
deliver its encapsulated compound. To do so, observations
and quantification of internalization were first carried out on
two-dimension (2D) conventional monolayer cell culture.
Then, three-dimension (3D) HCT-116 spheroids served as
model for tumor. HCT-116 spheroids have already been used
as an acknowledged 3D tumor model reducing the gap
between in vitro and in vivo outcomes (Chopinet et al., 2012;
Gibot et al., 2014, 2013; Till et al., 2016b, 2016c). For the
model of translocation across endothelium, an adaptation of
transwell assays (on Boyden chambers) was used. Well-docu-
mented for chemotaxis, transwell assays only start to be
used to study the passage of nanomaterials across biological
barriers such as mucus, aortic, brain, and intestinal barriers
(Broughton-Head et al., 2007; Jayagopal et al., 2008; Cohen
et al., 2014; Shah et al., 2015; Kasper et al., 2016; Lin et al.,
2016; Peuschel et al., 2016; Zhao et al., 2016; Boya et al.,
2017; Hsiao et al., 2017). So far, this promising and flexible
technique had not been used with polymeric nanocarriers or
to mimic the endothelium. It handily provided information
on in vitro behaviors of the PEO-PCL nanocarriers, before
confirmation of the results by preliminary in vivo
experiments.
Materials and methods
Chemicals
Poly(ethylene oxide-b-e-caprolactone) with respective block
molecular weights of 5000 and 4000 g.mol1 (PEO-PCL 5-4),
5000 and 11000 g.mol1 (PEO-PCL 5-11), and anthracene-ter-
minated polycaprolactone (8100 g.mol1) were obtained
from Polymer Source Inc. (Dorval, Canada). 3,3’-
Dioctadecyloxacarbo-cyanine perchlorate fluorophore (DiO)
was purchased from Invitrogen Life Technologies (Saint
Aubin, France). The solvents were purchased from SDS (Seihl,
France) and unless specified otherwise, all other chemicals
were purchased from Sigma-Aldrich (Saint-Quentin
Fallavier, France).
Nanocarrier formulations and characterizations
Nanocarrier formulations
Formulation of polymeric micelles by a co-solvent approach
was carried out as previously described (Knop et al., 2009).
Briefly, 20mg of PEO-PCL 5-4 with or without DiO (2% mol)
or PCL-Anthracene (10% mol) were dispersed in 0.4mL acet-
one. This solution was added dropwise into 5mL of ultrapure
filtered water under continuous stirring. The resulting micelle
suspension was left standing 48 h at room temperature for
the acetone to evaporate. Polymersomes were formed by
film rehydration-extrusion as previously described (Till et al.,
2014, 2016b). A solution of 20mg of PEO-PCL 5-11 in 1mL
chloroform with or without DiO (2% mol) or PCL-Anthracene
(10% mol) was evaporated on a rotary evaporator. The result-
ing film was further dried under vacuum for at least 2 h.
After rehydration in 2mL of ultrapure filtered water, the sam-
ple was heated at 65 C for 30min without stirring, and 1 h
in an ultrasonic bath. The sample was afterward extruded 10
times through a 0.4 mm cutoff polycarbonate membrane
using a Polar Avanti Lipids mini-extruding system (Avanti
Polar Lipids Inc., Alabaster, USA).
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Nanocarrier physicochemical characterizations
The morphology of the polymeric micelles and polymer-
somes was checked using transmission electronic microscopy
(TEM) on a Hitachi HT7700 microscope (Hitachi High-
Technologies Corp., Tokyo, Japan). A copper grid coated with
a carbon membrane was briefly immerged in a drop of
micelles or polymersomes suspension. After removal of the
excess of liquid on an absorbent paper, a few drops of a
uranyl acetate solution were let for absorbance onto the grid
for 10 s. The grid was finally dried for 3min under a lamp
before observations (acceleration voltage of 75 kV).
The nanocarriers hydrodynamic diameter was assessed
using dynamic light scattering (DLS) on a Malvern Zetasizer
Nano ZS (Malvern, Orsay, France). Samples were analyzed in
triplicate undiluted at 25 C with a 60 s record, standard laser
at 633 nm and a 173 angle. Data were analyzed using the
general-purpose non-negative least-squares method. The typ-
ical accuracy for these measurements was 10–20% for sys-
tems exhibiting a poly-dispersity index lower than 0.4.
Further measurements were carried out on polymersomes to
confirm their hydrodynamic diameters and polydispersity
using Nanoparticle Tracking Analysis (NTA, NanoSight device
from Malvern, Orsay, France). Samples were analyzed diluted
at 1/10,000 at 25 C with a 60 s record. Zeta potentials were
measured on a Malvern Zetasizer Nano ZS at 25 C with
undiluted samples using Smoluchowski’s model. Nanocarriers
were diluted at 2% v/v in ultrapure filtrated water before
being analyzed using UV-vis (Specord S 600, Jena, Germany)
from 200 to 800 nm at 37 C. Dialyses of the nanocarriers
were carried out to measure the DiO release over time such
as in Guo’s study (Guo et al., 2017). Nanocarriers were
diluted in ultrapure water to 1 mM of DiO. 2mL of this sus-
pension were dialyzed using mini Dialysis Kit at 1 kDa cutoff
(GE, Pittsburgh, USA) against 500mL of ultrapure water at
37 C under slow stirring. Samples were analyzed by UV-vis
at 0, 15, and 24 h. Further characterizations of PEO-PCL 5-11
morphology were performed using light and neutron scatter-
ing, as well as cryo-Transmission Electron Microscopy and are
described in Supplementary information S2–S4.
Internalization of nanocarriers by tumors and
endothelial cells in conventional 2D monolayers and 3D
tumor spheroids
Human colorectal carcinoma cells (HCT-116) were purchased
from ATCC (#CCL-247). HCT-116 were grown in Dulbecco’s
modified Eagles medium (DMEM) with 4.5 g.L1 glucose,
L-glutamine and pyruvate, supplemented with 10% (v/v)
heat-inactivated fetal calf serum, 100U.mL1 penicillin and
100lg.mL1 streptomycin and used for experiments until
passage 20. DMEM cell culture medium was purchased from
Invitrogen Life Technologies (Saint Aubin, France), penicillin,
streptomycin, and phosphate-buffered saline (PBS) were
obtained from Sigma-Aldrich (Saint Quentin Fallavier,
France). Primary human umbilical vein endothelial cells
(HUVEC) were obtained from Lifeline Cell Technology
(Frederick, USA) at passage 2 from a single donor. HUVEC
were grown in EBM-2 medium complemented with the EGM-
2MV bullet kit without gentamycine, plus 100U.mL1 penicil-
lin and 100 lg.mL1 streptomycin and used for experiments
until passage 6 in order to preserve their differentiated
phenotype. EBM-2 medium and EGM-2MV supplement kit
were obtained from Lonza (Walkersvlle, USA). Cells were
maintained at 37 C in a humidified atmosphere containing
5% CO2.
Large aggregates of nanocarriers appeared in test condi-
tions due to interaction between the polymeric nanocarriers
and cell-treated plastic culture plates (five different brands
tested). These aggregates have been avoided by the func-
tionalization of cell culture plates with sterilized gelatin 0.4%
in ultrapure water (see Supplementary data S1). Gelatin was
purchased from Fisher Scientific (Loughborough, UK). A vol-
ume of gelatin equivalent to the planned volume of culture
medium was added into the plates. They were then stored
at 4 C overnight before the gelatin was removed and the
plates let dry for a few minutes under a laminar flow hood
before use. Gelatin coating was chosen because of its high
biocompatibility with cells.
First, cell viability was assessed by Prestoblue reagent
(Invitrogen Life Technologies, Saint Aubin, France). Briefly,
HCT-116 cells were seeded in 96-well plates at 30,000 cells/
well, HUVEC at 15,000 cells/well and allowed growing for
24 h. Nanocarriers or DiO alone were then added (diluted at
50, 10, and 1 mM polymer and equivalent in DiO based on
polymersomes content) for the toxicity assessment. After an
incubation of 24 h, cells were then rinsed three times with
PBS, 90 mL of culture medium and 10 mL of PrestoBlue were
added. The plates were incubated at 37 C, 5% CO2 for
30min before absorbance reading at 570 nm and 600 nm on
a spectrophotometer (Clariostar, BMG Labtech,
Ortenberg, Germany).
DiO internalization was then visualized using confocal
microscopy on classical 2D monolayer. HCT-116 and HUVEC
were seeded in chambered coverglass previously functional-
ized with gelatin. After 24 h, cells were incubated with nano-
carriers at 50 mM polymer (corresponding to 1 mM DiO) for an
additional 24 h. Fresh cells were then rinsed three times with
PBS and directly observed using confocal microscopy on a
Fluoview FV1000 (Olympus, Rungis, France) after nuclei coun-
terstaining with Hoechst, a fluorescent DNA intercalant. Laser
wavelengths were 405 and 488 nm to observe Hoechst and
DiO fluorescence, respectively. The 40 objective was used.
Live cells were maintained at 37 C under 5% CO2.
Kinetics of internalization of nanocarriers were analyzed
on 2D monolayers by flow cytometry. 12-well plates were
seeded with 40,000 cells/wells after 24 h cells were incubated
with nanocarriers at 50 mM polymer for an additional 24 h. At
different time points, cells were trypsinized and transferred
to micro-cytometer tubes on ice. Cells were excited with a
laser at 488 nm and DiO fluorescence was read with FL1
channel on a FACSalibur (BD Bioscience, Singapore,
Singapore) with a total of at least 6000 cellular events col-
lected for each tube.
In 2D co-culture, plasma membranes of HCT-116 cells
were labeled with CellVue Claret Far Red Cell Linker accord-
ing to the manufacturer protocol. Seeding density was
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optimized to obtain a 50–50% concentration in HCT-116 and
HUVEC at the time of analysis (i.e. 48 h after seeding): 10,000
HCT-116 and 20,000 HUVEC/well in 12-well plates. After 24 h
of cell growth, then 24 h of incubation with nanocarriers, DiO
(488 nm excitation) and CellVue Claret (655 nm excitation)
fluorescences were read on the FACSalibur on FL1 and FL4
channels, respectively, avoiding thus compensations.
HCT-116 spheroids were produced by the non-adherent
techniques as previously described (Gibot et al., 2013). 5000
cells/well were seeded into gelatin-functionalized non-adher-
ent U bottom 96 well plates (Costar #7007). Cells grew into
spheroids for 5 days at 37 C, 5% CO2. Spheroids were then
harvested and introduced into new wells containing nanocar-
riers at 50 mM polymer in fresh medium. After 24 h of expos-
ure, spheroids were rinsed twice in PBS and deposited on a
chambered slide. DiO penetration in the spheroids was
detected by a two-photon microscopy LSM 7MP device
(Zeiss, Marly Le Roi Cedex, France) with a 20 objective, at
room temperature. Chameleon Ultra 2 wavelength was set
at 800 nm.
In vitro and in vivo nanocarriers translocation across
the endothelium
Transwells with post-confluent HUVEC monolayer were used
to mimic the endothelium. Cells were seeded on 6.5mm
transwell inserts with 0.4lm pore polyester membrane
(Corning, New York, USA). In optimized conditions, 100,000
HUVEC were seeded on the top chamber (donor chamber) in
100mL of culture medium, whereas the bottom chamber
(receptor chamber) was filled with 600 mL of culture medium
for 48 h of incubation at 37 C, 5% CO2. The HUVEC mono-
layer was characterized using hematoxylin-eosin staining,
scanning, and transmission electronic microscopy (SEM and
TEM) and trans-endothelial resistance (TEER) measurement.
After histological staining with Hematoxyling and Eosin col-
orant, membrane was cut out and mounted on a glass slide
for imaging on a Leica MacroFluo device (Leica, Nanterre,
France). TEM images were acquired on the Hitachi HT7700
microscope (Hitachi High-Technologies Corp., Tokyo, Japan),
whereas SEM images were obtained with the Quanta 250
FEG (FEI, Oregon, USA). TEER was measured over time during
the HUVEC monolayer formation with the EVOM-2 Volt-Ohm
Meter and the ENDOHM-6 (WPI, Berlin, Germany). After 48 h
of HUVEC monolayer formation on the inserts, the medium
of the donor chamber was replaced by 100 mL of medium
containing DiO-charged nanocarriers at a concentration of
50mM of polymer. After another 24 h of incubation, the level
of DiO in the receptor chamber was analyzed by fluores-
cence measurement at 488 nm on the fluorimeter Clariostar
(BMG Labtech, Ortenberg, Germany). These levels of DiO
were normalized to those of acellular controls. Nanocarriers
both tagged with DiO (charged in the core of the micelles or
polymersomes) and Anthracene (covalently linked to PCL)
were used to distinguish the fate of the fluorophore and the
polymers with a second fluorescence reading at 355 nm.
DiO passage was also assessed in an inflammatory con-
text, to get closer to the context of the nanocarriers passage
from blood vessels to tumor through altered endothelium.
During the HUVEC monolayer formation on the inserts, at
24 h, the receptor chamber medium was replaced by
medium with 600 mL of tumor necrosis factor a (TNF-a) at
100U.mL1. The experiment was then carried out as previ-
ously explained. Another step to enhance the endothelium
model was to seed tumor cells in the bottom of the receptor
well. 30,000 HCT-116 cells were thus seeded on the bottom
of the 24-well plate just before plating HUVEC cells on the
membrane above. Medium fluorescence was read with the
fluorimeter, and cell fluorescence (for both HUVEC and HCT-
116) was read with the flow cytometer.
In vivo early experiments were conducted to complete the
in vitro findings. All animal experiments were conducted in
agreement with the official guidelines of EU Directive 2010/
63/EU and approved by the local ethics committee as a pilot
study on small number of mice. Female BALB/c-nu mice
were obtained from Janvier Labs (Saint Berthevin, France).
Preliminary tests have shown that the DiO dose used in vitro
(50 mM polymer were equivalent to 1mM DiO) was too low to
detect the fluorescence in vivo. Therefore, nanocarriers
charged at 20% mol DiO instead of 2% mol DiO were formu-
lated. Samples were diluted with PBS 10 to retrieve physio-
logical osmolarity. Mice bearing sub-cutaneous established
human HCT-116 tumors were treated with either control, DiO
alone, PEO-PCL 5-4 micelles loaded with 20% mol DiO, or
PEO-PCL 5-11 polymersomes loaded with 20% mol DiO. The
concentration of DiO alone was equivalent to the DiO con-
centration in polymersomes, hence superior to the micelles
one. A retro-orbital injection of 100 mL was carried out on
one mouse per condition. At 24 h post-injection, all mice
were sacrificed for further tissue analyses. Briefly, fluores-
cence of the whole organs of sacrificed mice was directly
observed under Macrofluo microscope (Leica, Wetzlar,
Germany) equipped with a cooled CCD camera (Roper
Coolsnap HQ, Photometrics, Tucson, AZ) with a fluorescent
filter at 488 nm, with a special focus on tumor tissue.
Fluorescent pictures were obtained by use of CRI
MicroColor 2 Liquid Crystal Technology. Harvested tumors
were fixed in formol (Sigma) for 24 h at 4 C and then
immersed for 2 h at 4 C in 10% sucrose in PBS followed by
an overnight incubation at 4 C with 30% sucrose in PBS, in
order to preserve tissue architecture after cryopreservation.
Tumors were then embedded in optimal cutting temperature
compound (OCT) (Electron Microscopy Sciences, Hatfield,
USA) and stored at 80 C. Cryosections of 8 mm thick were
generated on a LEICA CM3050 cryostat. Tumors cryosections
were analyzed by immunofluorescence to detect murine
endothelial cells thanks to a specific endothelial tight junc-
tion CD-31 (also named PECAM1) and nuclei with Hoechst.
Briefly, the slides were rinsed with demineralized water to
remove OCT, saturated with MaxBlock Blocking (Active Motif,
La Hulpe, Belgium), rinsed and then exposed to anti-CD-31
purified Rat Anti-Mouse primary antibody (BD, Franklin Lakes,
USA) at 1/400 in Dako antibody diluent (Dako, Glostrup,
Denmark), at 4 C, overnight. The slides were then rinsed and
incubated at room temperature for 30min with a secondary
antibody coupled to Alexa Fluor 594 Chicken Anti-Rat IgG
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(emission in the red wavelengths, from Thermo Fisher
Scientific, Waltham, USA) and DNA intercalant Hoechst at 1/
500 in Dako antibody diluent (Dako, Glostrup, Denmark) to
counterstain nuclei in blue. Slides were, afterward, rinsed
with PBS and demineralized water, and a cover-glass was
mounted using Dako mounting medium (Dako, Glostrup,
Denmark). Observations were carried out with the Fluoview
FV1000 confocal microscope. Eventually, red fluorescence
(594 nm excitation) corresponds to CD-31 of murine endothe-
lial cells, green fluorescence (488 nm excitation) to DiO, and
blue (450 nm excitation) to nuclei.
Statistics
Triplicates were collected for each in vitro experiment, each
experiment being carried out independently at least three
times. The data set was assessed using Fisher and Student’s
t-test (bilateral and difference in variances determined by
Fisher test). All data were expressed as mean± standard devi-
ation, and overall statistical significance was set at p< .05.
Results
Micelle and polymersome nanocarriers characterizations
Both PEO-PCL 5-4 micelles or PEO-PCL 5-11 polymersomes
exhibited a spherical shape (Figure 1(A,B)), with larger
dimensions for polymersomes as confirmed by hydrodynamic
diameter measurements using DLS (Figure 1(C) and Table 1).
Further diameter analyses were conducted using
Nanoparticle Tracking Analysis (NTA) for polymersomes only,
as micelles were under the limit of detection of the NTA
device (Figure 1(D)). The morphology of these vesicles was
thoroughly characterized in a previous study (Till et al.,
2014), and further measurements (SLS/DLS characterization,
Field Flow Fractionation, SANS, and cryo-TEM) confirmed
these findings (supplementary data, Figure S2–S4). No signifi-
cant change in diameter was observed between empty and
DiO-charged nanocarriers. Zeta potentials analyses showed
slightly negative surface charges (Table 1), and UV-vis meas-
urements revealed a net encapsulation of the DiO with a sin-
gle peak around 490 nm (Figure 1(E)). The UV-vis signal and
diameter stability were examined at room temperature over
4 or 9 days, respectively (Supplementary data Figure S5). The
hydrodynamic diameters and DiO specific peak area or
height remained constant, which confirmed that the nano-
carriers can be stored for a few days at room temperature.
To examine possible leakage of the DiO probe, the DiO
release from the nanocarriers diluted at 50 mM polymer
(equivalent to 1 mM DiO, as used in the next assays) was
assessed at 37 C, over 24 h, by dialysis in ultrapure water.
No significant signal was detected in the external solution. In
the dialysis tube, there was no significant decrease of the
peak area and of the peak height except for micelles at 24 h
(Supplementary data Table S1). This slight decrease in peak
height for micelles was not significantly different from the
Figure 1. Micelles (PEO-PCL 5-4) and polymersomes (PEO-PCL 5-11) size and charge characterizations: Transmission electron microscopy (A,B); DLS analyses (C);
nanoparticle tracking analyses (D); and UV-vis analyses (E).
Table 1. Micelles and polymersomes physicochemical analysis: DLS hydro-
dynamic diameter (DH) in number and intensity average, NTA hydrodynamic
diameter, and Zeta potential measurements.
Empty Charged with 2% mol DiO
Micelles PEO-PCL 5-4
DH in number average (nm)
DH in intensity average (nm)
Zeta potential (mV)
14 ± 1
24 ± 0
13 ± 3
14 ± 2
25 ± 4
11 ± 4
Polymersomes PEO-PCL 5-11
DH in number average (nm)
DH in intensity average (nm)
NTA diameter (nm)
Zeta potential (mV)
72 ± 6
135 ± 11
111 ± 9
4 ± 1
65 ± 5
117 ± 10
93 ± 10
3 ± 1
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one showed for the control and could be imputable to the
experience itself: decrease of the fluorescence at each
UV reading.
Internalization of nanocarriers by human endothelial
and tumor cells
Internalization of mono-and co-cultures in monolayer
Cytotoxicity was assessed as a preliminary and mandatory
step to ensure suitable safety of the systems (Supplementary
data Figure S6). After 24 h of exposure, as expected, none of
the treatments decreased significantly HUVEC and HCT-116
viability. Live HUVEC and HCT-116 were observed using con-
focal microscopy after 24 h exposure to nanocarriers charged
with DiO (Supplementary data Figure S7). After exposure of
HUVEC to micelles, DiO was visible in the cytoplasm.
Polymersomes induced a more intense although blurrier
fluorescence. A slight fluorescent background is notable for
the non-treated HUVEC but discernible from the DiO fluores-
cence. In the HCT-116 cells with smaller dimensions, the
detection of DiO from micelles is less obvious compared to
the control. Nonetheless, after exposure to polymersomes,
HCT-116 was clearly marked.
Flow cytometry confirmed DiO internalization using
HUVEC, and HCT-116 cells treated with either micelles or pol-
ymersomes. A more efficient delivery of DiO by micelles was
observed in HUVEC. Both the proportion of cells labeled with
DiO (Figure 2(A)) and the intensity of DiO fluorescence in
those cells (Figure 2(B)) increased with time. HUVEC treated
with micelles exhibited the fastest internalization process
with more than 60% labeled cells after only 0.5 h of exposure
and a plateau around 95% reached after 4 h. The three other
conditions led to a similar kinetic in three steps: first, a slow
increase of the internalization rate; second, after 2 h a crucial
acceleration until eventually a plateau was reached. The pro-
portion of labeled cells at the plateau is equivalent for
HUVEC or HCT-116 exposed to micelles (around 97%),
whereas slightly underneath for cells exposed to polymer-
somes (95% and 92%, respectively). HUVEC treated with
micelles also showed the highest intensity of fluorescence,
whereas those treated with polymersomes exhibited a lower
intensity of fluorescence but still higher than those for HCT-
116 treated with micelles or polymersomes. In the co-culture
assay, the tendency for HUVEC to integrate more DiO, espe-
cially, from micelles was kept: slightly more HUVEC than
HCT-116 were labeled for both nanocarriers (Figure 2(C)) and
micelles induced significantly more fluorescence intensity in
labeled HUVEC than in HCT-116 (Figure 2(D)). However, there
was no real specificity of the nanocarriers as the proportion
of cells of each type labeled with DiO was not significantly
different when exposed to micelles (51% of HUVEC and 46%
of HCT-116) or polymersomes (50% and 34%).
DiO distribution in 3D tumor spheroids
The internalization capacity of DiO from the nanocarriers,
proven in conventional 2D culture, was then tested in 3D
tumor spheroids. Figure 3 displays two-photon microscopy
images of the spheroids treated with nanocarriers for 24 h.
DiO internalization by the first cell layers of the spheroid was
Figure 2. Quantification by flow cytometry of internalization of micelles and polymersomes charged with DiO in HUVEC and HCT-116: kinetics in monoculture (A,B)
and 24 h internalization in co-culture (C,D).
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clearly observable for either micelle (Figure 3(A)) or polymer-
somes (Figure 3(B)). The penetration capacity was measured
on an optical section 50 mm depth from the spheroid surface
(Figure 3(C,D)). DiO from micelles penetrated significantly fur-
ther than DiO from polymersomes (85 ± 35mm and
68± 29 mm, respectively). Depending on their characteristics,
the two nanocarriers were thus able to deliver their charge
in the first 5–10 cell layers of a tumor spheroid in 24 h, which
is crucial for the delivery of therapeutic agents on site. These
results mean that once the endothelium barrier is crossed,
micelles will tend to be more widely spread within surround-
ing tumor tissue.
Nanocarriers translocation across the
endothelium barrier
Passage of nanocarriers through the endothelium model
After 48 h of the HUVEC monolayer growth and the produc-
tion of a cohesive endothelium was observed (as shown in
Supplementary Figure S8 and confirmed using TEER meas-
urements in Figure S9(A)), nanocarriers were introduced in
the donor chamber for a 24 h incubation. Figure 4(A) shows
a significant difference in the DiO fluorescence level found in
the receptor chamber for micelles and polymersomes. DiO
encapsulated in micelles crossed the endothelium almost
twice less than DiO encapsulated in polymersomes (8% and
15%, respectively). We showed in 2D classical monolayer
(Figure 2) that DiO encapsulated in micelles was massively
trapped inside HUVEC after incubation, this process could
explain why micelles are less available for passage across the
endothelium and then less detected in the receptor cham-
ber. At this step, it was crucial to determine if DiO crossed
the endothelium freely after having been released from the
nanocarriers, or if the nanocarriers crossed it along with the
DiO. Micelles and polymersomes charged with DiO and
labeled with Anthracene covalently linked to the polymer
PCL were formulated to determine this. The thorough char-
acterization of these nanocarriers showed that their physico-
chemical characteristics were similar to those of empty
nanocarriers as well as for nanocarriers charged with DiO
only (Supplementary Figure S10). The endothelium model
experiment was carried out in the same manner as previ-
ously. Anthracene fluorescence measurements in the recep-
tor chamber showed that around 50% of the Anthracene
crossed the endothelial monolayer for both micelles and pol-
ymersomes (52% and 48% respectively) (Figure 4(B)). The dif-
ference between the two types of nanocarriers was not
significant. It appeared thus that the polymers and the DiO
were able to cross the endothelium even if it remained
unclear if the nanocarriers were still intact afterward.
In a tumor context endothelium is affected by the micro-
environment, thus a pro-inflammatory cytokine known to
activate endothelial cells (TNF-a) was added in the receptor
Figure 3. DiO penetration in 3D tumor spheroid depending on the nanocarriers: two-photon microscopy images of the mean intensity projection of DiO fluores-
cence from HCT-116 spheroids exposed for 24 h to micelles (A) and polymersomes (B). C and D are optical sections at z¼ 50 mm depth of the spheroid A and B,
respectively.
1772 A. FIGAROL ET AL.
chamber to simulate such altered environment. TEER meas-
urements confirmed a disruption of the endothelium barrier
(Supplementary Figure S9(B)). After 24 h of incubation with
charged nanocarriers, the DiO levels in the receptor chamber
were higher than in healthy condition, especially for micelles,
which smoothed the difference between them and polymer-
somes (Figure 4(C)). To mimic more closely cells interactions
as observed in the micro-environment in vivo, HCT-116
tumor cells were seeded in the bottom of the receptor well
in co-culture. Approximately two-fold higher levels of DiO
were found in the receptor chamber, indicating a significant
effect of soluble factors released by tumor cells on endothe-
lium integrity (Figure 4D). Those results underlined the alter-
ation of the endothelium barrier function in pathological
conditions. Additionally, flow cytometry experiments were
performed after cell detachment to give an indication of the
amount of DiO retained in the model of endothelium layer
and tumor (Figure 4(E,F)). DiO from micelles labeled a
significantly higher amount of HUVEC but at intensities lower
than DiO from polymersomes. A significantly higher propor-
tion of HCT-116 was labeled with DiO from micelles rather
than from polymersomes (50% and 13%, respectively).
Additionally, the intensity of HCT-116 labeling from polymer-
somes was very low and not significantly different from the
control. Thus, even if polymersomes crossed more easily the
endothelial barrier, hence more DiO is available in receptor
chamber, tumor cells were not prompt to integrate it, con-
trary to DiO from micelles.
In vivo early results
A preliminary in vivo study was carried out to confirm the in
vitro results. Nanocarriers charged with 20% mol DiO were
formulated, especially for the in vivo experiments. Their phys-
icochemical characteristics were comparable to nanocarriers
Figure 4. Quantification of nanocarriers’ passage across the endothelium barrier after 24 h of incubation: DiO fluorescence in the receptor chamber (A), Anthracene
fluorescence in the receptor chamber (B), DiO fluorescence in the receptor chamber in pro-inflammatory condition (C), DiO fluorescence in the receptor chamber in
presence of tumor HCT-116 (D). Intracellular quantification of nanocarriers by flow cytometry: proportion of labeled cells (E), intensity of DiO fluorescence in labeled
cells (F). p< .05. NS: non-significant difference. For each nanocarrier, the DiO fluorescence was significantly lower in the healthy condition compared to the dis-
turb conditions (with TNF-a or in coculture).
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with 2% mol DiO except for their UV-vis signal
(Supplementary Figure S11). Right after retro-orbital injec-
tions, no specific fluorescence was seen through the skin,
apart from the skin autofluorescence itself. Twenty-four hours
after injection, the mice were sacrificed, the main storage
organs, lungs, livers, and kidneys, were observed
(Supplementary data Figure S12), but a focus was made on
explanted tumors. In the mouse treated with DiO alone, the
tumor showed no fluorescence discernable from the controls
(Figure 5(A,B)). The tumor from the mouse treated with
Figure 5. Macroscopic and microscopic (cryosection) fluorescent pictures of explanted HCT-116 tumors 24 h after retro-orbital injection in mice of 100mL of PBS
(A,E), DiO alone (B,F), micelles charged with 20% mol DiO (C,G), or polymersomes charged with 20% mol DiO (D,H). DiO fluorescence (green), and in cryosection
nuclei stained with Hoechst (blue), and CD-31þ murine endothelial cells detected by immunofluorescence (red).
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micelles displayed a very intense fluorescence (Figure 5(C))
and the one treated with polymersomes a lower but still dis-
tinct fluorescence (Figure 5(D)). Interestingly, although fluor-
escence signal from micelles was homogeneously spread all
over the tumor, the one from polymersomes seemed to
closely follow the vasculature architecture. Further analyses
of the tumors were conducted using confocal microscopic
observations of cryo-sections of each tumor after an immu-
nolabelling against CD-31, a protein specific of endothelial
cells constituting the endothelium in blood vessels (Figure
5(E–H)). As for macroscopic observations, cryo-sections asso-
ciated with micelles exhibited the highest DiO fluorescence
signal. DiO fluorescence from micelles was located in the
cytoplasm of the cells up to tens of micrometers from the
blood vessels and did not seem to be specifically associated
with endothelial cells. On the contrary, DiO fluorescence
from polymersomes was mainly detected close to cells posi-
tively labeled for CD-31. The tumor of the mouse treated
with DiO alone led to a cryosection with a diffuse DiO fluor-
escence that was not visible at a macroscopic scale. Overall,
it suggested that DiO alone can reach the tumor but in a
largely less specific and efficient way than DiO encapsulated
in nanocarriers. Moreover, it confirms that DiO from micelles
diffuse easily in the tumor, whereas polymersomes were con-
fined in its vicinity despite their enhanced capacity to cross
the endothelium.
Discussion
Previously, the two polymeric nanocarriers studied here,
PEO-PCL 5-4 micelles and PEO-PCL 5-11 polymersomes, have
successfully shown their capacity to deliver Pheophorbide A
for anti-cancer photodynamic therapy (Knop et al., 2009;
Gibot et al., 2014; Till et al., 2016b). Equivalent elongated
self-assemblies (PEO-PCL 2-7) did not show any advantages
in terms of efficacy in these former studies, thus the focus
was made on spherical micelles and polymersomes for fur-
ther studies on such systems. In this work, we took a step
back and focused on the path of the nanocarriers and its
encapsulated drug from the blood vessel to the tumor across
the endothelium. Two main questions were to answer. First,
do nanocarriers interact with endothelial cells from the blood
vessel, and if so, is there a specificity in the interaction with
endothelial or cancer cells? Second, are nanocarriers able to
cross an endothelial monolayer in healthy conditions or in
the tumor region, if so at which proportion?
The first question was assessed by studying the in vitro
internalization of PEO-PCL micelles and polymersomes in
human primary endothelial cells HUVEC and colorectal HCT-
116 tumor cells. It was demonstrated that DiO was internal-
ized by both cell types in 2D cell culture and in 3D HCT-116
tumor spheroids. A previous study from our laboratories sug-
gested that antitumor drug release occurred by direct jump
from the nanocarriers PEO-PCL micelles (PEO-PCL 2-2.6 and
5-4) to the human colon cancer cells (HCT-116) (Till et al.,
2016a). On the other hand, the review of Christian et al.
(2009) concluded that the main release mechanism of encap-
sulated agents from PEO-PCL polymersomes is through PCL
hydrolytic degradation, which is accelerated intracellularly in
endolysosomes, thus after internalization of the nanocarriers.
It has also been shown that endocytosis played a crucial role
in the internalization of other PEO-based micelles (Zhang
et al., 2016). As confirmed by the co-culture experiments in
monolayer, DiO signal did not seem to be cell type specific.
Small differences were nonetheless observed, in kinetics,
intensity, and proportion of labeled cells, more important for
HUVEC. These differences were also linked to the nanocar-
riers type. DiO signal was faster and more intense for
micelles compared to polymersomes. It was observed, espe-
cially, in HUVEC, but the trend was still present in HCT-116.
DiO from micelles were also internalized deeper into HCT-
116 tumor spheroids than polymersomes. If we consider the
possible internalization of the nanocarrier itself and not just
the encapsulated compound, these results were not surpris-
ing. Size has indeed been widely documented as a factor
influencing cell internalization of nanomaterials (Massignani
et al., 2009; Chang et al., 2014; Ferrari et al., 2014). The nano-
carriers of our study presented indeed very dissimilar diame-
ters for a same surface chemistry, size is thus thought to be
the most influent parameter here. However, Zhang et al.
(2013) suggested that at equal size, the internalization of
copolymer nanocarriers in HUVEC and tumor cells is driven
by the hydrophilic-hydrophobic ratio. The PEO-PCL 5-5
micelles of that study, which are the closest from our PEO-
PCL 5-4 micelles, exhibited, as found here, the highest
uptake efficiency in different cell lines. Other micelles, closer
in size to our PEO-PCL 5-11 polymersomes, with low hydro-
philic-hydrophobic ratio, showed also lower uptake effi-
ciency. Copolymers ratio resulting in different nanocarrier’s
size and surface properties could influence the internalization
of endothelial and cancer cells, without inducing specificity
for one or the other type of cells.
The second part of this work gave evidence that nanocar-
riers could cross an endothelium model, and at higher pro-
portions when endothelial cells were activated with TNFa or
in distressed environments compared to a healthy one.
Approximately, 17% of polymeric nanocarriers could cross a
confluent HUVEC monolayer in healthy conditions. After dis-
ruptions of the HUVEC monolayer by TNF-a or co-culture
with tumor HCT-116 in the receptor well, up to 28% of the
nanocarriers could cross it. It is known that in general health
condition, the passage should be very restricted with nano-
carriers as only transcellular passage should be possible with
diameter higher than 15 nm (Komarova & Malik, 2010).
However, such translocation of some nanomaterials across a
healthy monolayer of endothelial cells was already seen in
the literature. Jayagopal et al. (2008) observed translocation
of solid lipid nanoparticles through endothelial cells from
bovine aortas. Zhao and Lin worked on endothelial layers
from blood-brain barrier, for Zhao, there was a possible
translocation of the nanoparticles, or for Lin, at least of the
nanocarriers charge (Lin et al., 2016; Zhao et al., 2016). The
increase in DiO’s passage induced by a cytokine or cancer
cells was more expected. Both para- and transcellular path-
way are triggered by external stimuli, and the presence of
cancerous cells or disturbing agent can increase the
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transport rate and contribute to the creation of a fenestrated
discontinuous endothelium (Dvorak et al., 1988; Baban &
Seymour, 1998; Maeda, 2001). Interestingly, DiO intensity in
HUVEC quantified using flow cytometry was lower when
HCT-116 was seeded on the receptor cells. This could mean
that HCT-116 liberates soluble factors or extracellular vesicles
reducing the uptake of HUVEC and inducing the higher per-
meability in this co-culture model. Baban & Seymour (1998)
suggested indeed that vascular permeability was regulated
by tumor-secreted growth factors notably vascular endothe-
lial growth factor (VEGF), a cytokine is known to be
expressed by HCT-116 cells (Ahluwalia et al., 2013).
Furthermore, both in healthy conditions and in co-culture
condition with tumor cells, the proportion of DiO crossing
the endothelium was significantly lower for micelles com-
pared to polymersomes. Despite that, HCT-116 on the bot-
tom well was still more labeled with DiO from micelles than
polymersomes. It indicates that even if less DiO from micelles
were available in the bottom well, it was more prompt to be
internalized by cancer cells. These results are in accordance
with 2D and 3D observations led on 3D tumor spheroids
where DiO from micelles was able to deeper penetrate in
tumor spheroids than DiO from polymersomes. Further
enhancement of the tumor-like environment could be made
to keep investigating this. A longer pre-culture of the endo-
thelial cells on the inserts with 3D spheroids in the lower
chamber could be set up, with an exhaustive investigation of
the factors released by tumor cells. A model of blood vessel
wall including a layer of endothelial cells and several layers
of muscular cells was developed by Chetprayoon et al. (2015,
2016) and could be another step toward a complete 3D
blood vessel in vitro produced by tissue engineering.
To answer the question of the integrity of the nanocar-
riers after crossing the endothelium, Anthracene covalently
linked with PCL was used as a label for the nanocarriers in
the second part of this study. However, its detection using
confocal microscopy or flow cytometry was not technically
feasible. A Fluorescence Resonance Energy Transfer (FRET)
experiment was considered to answer this question, unfortu-
nately, commercial availability of labeled PCL is very limited
and no correct pair of donor and acceptor could be found.
Theoretically, this couple—composed of encapsulated DiO
and another fluorophore covalently linked to the polymers—
would have expressed a high specific signal when in close
vicinity (1–10 nm typically). This signal should drastically fall
when the distance increases, thus indicating that the DiO is
not in close vicinity of the polymer anymore; hence, it was
released from the nanocarrier. But, we still confirmed that
Anthracene covalently linked to polymers had indeed
crossed endothelial monolayer because it was found in the
lower chamber of the endothelium model. However, as pre-
viously mentioned, it was not technically feasible to discern
whether the nanocarriers were intact and still encapsulating
the DiO.
Early in vivo results validated the endothelium transwell
model by confirming our previous findings. Nanocarriers
charged with 20% mol DiO were formulated for this experi-
ment, with a fluorescence signal interestingly lower for
polymersomes than for micelles. DiO self-quenching could
be the issue here (Heberle et al., 2005; Buboltz et al., 2007;
Zhao et al., 2007; Chen et al., 2008). However, it was not
seen for micelles although their core is expected to be nar-
rower than polymersome inner space. This could also be due
to a lower encapsulation capacity in the polymersomes des-
pite their larger diameter compared to micelles and the gen-
eral literature allegation (Balasubramanian et al., 2016).
Alibolandi et al. (2016) suggested, notably, that PEO in the
confined inner space of a polymersome induces a very
crowded environment that decreases its encapsulation cap-
acity. Nonetheless, the DiO level was sufficient to detect it
after injection in mice, allowing the in vivo experiment to be
carried out, but restraining comparison of DiO intensity from
micelles to polymersomes. DiO was observed in the lungs,
liver (especially for free DiO and DiO from micelles), and kid-
ney, but it was effectively more uptaken by tumor when
encapsulated in nanocarriers than as a free molecule. In cryo-
sections, it was seen that DiO from micelles diffused largely
in tumor cells, far from the vasculature, whereas DiO from
polymersomes stayed in the vicinity of blood vessels. It
matched with the hypothesis that micelles internalized faster
in a large number of cells, whereas polymersomes which
crossed the endothelium at higher amount are more slowly
internalized in cancer cells. A development of this in vivo
confirmation could be made by looking at the rate of intern-
alization and washing from the tumor as proposed in Ke’s
work (Ke et al., 2017, 2018).
Overall, we have seen that the polymeric nanocarriers
were internalized by endothelial and cancer cells, without
specificity in this interaction. Furthermore, around 17% of
nanocarriers could cross the endothelium model used herein
healthy condition. This proportion was increased in dis-
tressed environment of up to 28%. Nonetheless, important
losses of encapsulated compounds can be predicted,
induced by all nonspecific interactions with the endothelium
and translocation through the blood vessels in healthy area.
This has to be taken into account when designing a new
nanocarrier for nanomedicine, especially considering that
these losses seemed to be dependent on some physico-
chemical properties of the nanocarrier, such as its size. In a
radical change of paradigm, endothelial cells in non-cancer-
ous conditions could be considered as a good target for
those nanocarriers, especially for polymersomes. But for
more traditional anti-cancer therapy, other strategies such as
active-targeting of the nanocarriers should be further looked
into in order to enhance cell specificity (Peer et al., 2007;
Guo et al., 2016; Ke et al., 2018).
Conclusions
Nanocarriers, PEO-PCL 5-4 micelles and PEO-PCL 5-11 poly-
mersomes, presented the ability to cross the endothelium
barrier to reach tumor cells, but drug losses are expected
throughout this process. Internalization of the encapsulated
DiO was confirmed both in endothelial HUVEC cells and
tumor HCT-116 cells with no ostensible specificity.
Translocation through the endothelium model also occurred
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in healthy condition. It was nonetheless enhanced (from 17%
up to 28%) with the addition of a disturbing agent (TNF-a or
cancer cells) as suggested by the EPR theory. The two
studied polymeric nanocarriers shared the same surface
chemistry but were largely different in size. DiO internaliza-
tion was faster and more efficient with micelles than poly-
mersomes, especially in endothelial cells. This privileged
internalization could induce retention and explain the lower
rate of DiO from micelles crossing the endothelium model.
Despite a lower translocation capacity, DiO from micelles
was, however, once again more internalized in the cancer
cells seeded underneath the endothelial monolayer than DiO
from polymersomes. The in vivo early results eventually con-
firmed this distinct behavior between micelles and polymer-
somes. Finally, it seemed that micelles were more efficient
drug delivery systems than polymersomes but losses regard-
ing nonspecific internalization and translocation through the
blood vessel have yet to be taken into consideration. The
on-going development of in vitro endothelium and capillaries
models could benefit future investigations on the impact of
the nanocarriers’ physicochemical characteristics, aiming for
an improved ratio of administrated versus delivered dose.
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